With Fresh Pneumonia Data, Paratek To Seek 2018 Antibiotic Approval - Xconomy

Newsmax

With Fresh Pneumonia Data, Paratek To Seek 2018 Antibiotic Approval Xconomy The need for new antibiotics to battle drug-resistant bacteria is rising, and Paratek Pharmaceuticals has news that could give doctors a new weapon. Boston-based Paratek (NASDAQ: PRTK) reports that its antibiotic, omadacycline, has hit all its main and ... Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial PneumoniaP&T Community Paratek Pharma shares surge 30% after antibiotic study resultsMarketWatch all 4 news articles »

from Health - Google News http://ift.tt/2o3etPA